[{"orgOrder":0,"company":"Par Pharmaceutical","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Arginine Vasopressin","moa":"Vasopressin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Par Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Par Pharmaceutical \/ Par Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Par Pharmaceutical \/ Par Pharmaceutical"},{"orgOrder":0,"company":"Par Pharmaceutical","sponsor":"Endo International","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Par Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Par Pharmaceutical \/ Endo International","highestDevelopmentStatusID":"15","companyTruncated":"Par Pharmaceutical \/ Endo International"},{"orgOrder":0,"company":"Par Pharmaceutical","sponsor":"Nevakar","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Par Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pre-Filled Injection","sponsorNew":"Par Pharmaceutical \/ Par Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Par Pharmaceutical \/ Par Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals by Par Pharmaceutical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : Ephedrine Sulfate Injection (“Ephedrine”) in a prefilled syringe is a widely used injectable vasopressor agent indicated for the treatment of clinically important hypotension occurring during surgery.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 28, 2022

                          Lead Product(s) : Ephedrine Sulfate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Nevakar

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : The U.S. District Court for the District of Delaware issue a temporary restraining order and preliminary injunction preventing the launch of Eagle’s recently approved vasopressin product.

                          Product Name : Vasopressin-Generic

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          December 29, 2021

                          Lead Product(s) : Arginine Vasopressin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Eagle Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : Company has begun shipping varenicline, a generic version of Pfizer's Chantix® (varenicline) 0.5 mg and 1 mg tablets. Varenicline is a nicotinic receptor partial agonist indicated for use as an aid to smoking cessation treatment.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 22, 2021

                          Lead Product(s) : Varenicline Tartrate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Endo International

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 29, 2017

                          Lead Product(s) : Pimecrolimus

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          November 26, 2013

                          Lead Product(s) : Ciprofloxacin

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase III

                          Sponsor : Novum Pharmaceutical Research Services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          July 29, 2013

                          Lead Product(s) : Ciprofloxacin

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase III

                          Sponsor : Novum Pharmaceutical Research Services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 21, 2011

                          Lead Product(s) : Diclofenac

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Novum Pharmaceutical Research Services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 27, 2011

                          Lead Product(s) : Lisinopril

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : PharmaKinetics Laboratories

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 27, 2011

                          Lead Product(s) : Doxycycline

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Anapharm

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 27, 2011

                          Lead Product(s) : Doxycycline

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Anapharm

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank